Dược phẩm 📰 1 新闻 →

IMP

Dược phẩm Imexpharm

-0.18%

Mkt Cap 1.5T

9.5

Strong Sell

Sentiment

+1.00

Impact

1.00

Momentum

-0.04

Fundamentals

+0.00

Volume

0.54

新闻情绪

已分析文章

主要情绪

Negative

Negative 2

Neutral 1

Positive 1

最新新闻

Apr 20, 2026

VNDirect (VND) Q1 2026 Profit Up 43% as TP Securities (ORS) Surges 1,961%

VNDirect (VND) posted Q1 2026 pre-tax profit of VND 681 billion, a 43% year-on-year increase, as part of a broader earnings release wave. TP Securities (ORS) led with a 1,961% surge to VND 42 billion, while ACBS grew 67% to VND 303 billion, highlighting divergent performance in Vietnam's securities sector amid mixed market conditions.

earnings beat

10 Positive

Apr 10, 2026

The Ministry of Health has issued a directive to ensure a stable, timely, and reasonably priced supply of essential drugs, urging provinces, hospitals, and pharmaceutical companies to prevent shortages, hoarding, and unreasonable price increases while prioritizing domestic production.

↗ 外部来源

7 Neutral

Multiple executives at Imexpharm sell shares citing personal financial adjustments; other transactions include Diamond Properties reducing NVL holdings, OCB insider sales, and foreign fund buying SHS shares.

↗ 外部来源

6 Negative

Imexpharm (IMP) Executives Register to Sell Shares for Personal Financial Planning

Imexpharm (IMP) executives, including CEO Trần Thị Đào, registered to sell 607,400 shares (0.44% stake) from mid-April to mid-May 2026 for personal financial planning. The planned sales coincide with the company's annual meeting on April 22 and ambitious 2026 targets of VND 3,200B revenue (+9.8%) and VND 502B pre-tax profit (+12.6%).

insider trade

4 Negative